Table 2.

Univariate Cox Regression Analysis of Disease-free and Overall Survival in Relation to Clinicopathologic Features

Characteristics	Number of patients	Disease -free survival		Overall survival
		HR (95% CI)	P value	HR (95% CI)	P value
Gender
Females (ref)	88	1.00		1.00
Males	124	0.97 (0.70–1.34)	0.84	1.04 (0.74–1.46)	0.82
Age (yrs)			0.04		0.60
<60 (ref)	88	1.00		1.00
60–70	77	0.81 (0.57–1.16)	0.25	0.94 (0.65–1.36)	0.74
>70	47	0.56 (0.35–0.87)	0.01	0.78 (0.49– 1.26)	0.31
Blood loss	212	1.00 (1.00–1.00)	0.22	1.00 (1.00–1.00)	0.10
Neoadjuvant therapy			0.98		0.59
Group 1 (ref)	39	1.00		1.00
Group 2	66	0.80 (0.49–1.30)	0.37	0.73 (0.44–1.21)	0.23
Group 3	70	1.27 (0.80–2.01)	0.32	0.95 (0.59–1.55)	0.84
Group 4	32	1.50 (0.86–2.60)	0.15	0.99 (0.55–1.78)	0.97
Group 5	5	1.50 (0.53–4.30)	0.45	1.34 (0.47–3.85)	0.59
Tumor size
≤2cm (ref)	79	1.00		1.00
>2cm	133	1.29 (0.92–1.81)	0.14	1.24 (0.87– 1.76)	0.24
Margin
Negative (ref)	188	1.00		1.00
Positive	24	1.52 (0.95– 2.41)	0.08	1.88 (1.18–3.00)	0.008
Tumor differentiation
Well-moderate (ref)	134	1.00		1.00
Poor	78	1.23 (0.89–1.72)	0.21	1.29 (0.92–1.81)	0.15
Pathologic tumor stage
ypT1-ypT2 (ref)	13	1.00		1.00
ypT3	199	1.98 (0.93–4.23)	0.08	3.38 (1.25–9.15)	0.02
Lymph nodes
Negative (ref)	87	1.00		1.00
Positive	125	1.59 (1.14–2.22)	0.007	1.77 (1.24–2.53)	0.002
AJCC Stage			0.01		0.003
Stage IA and IB (ref)	10	1.00		1.00
Stage IIA	77	1.94 (0.77–4.86)	0.16	4.57 (1.11–18.88)	0.04
Stage IIB	125	2.84 (1.15–6.99)	0.02	6.99 (1.72–28.45)	0.007
Tumor invasion of muscular vessels
Absent (ref)	148	1.00		1.00
Present	64	2.09 (1.50–2.91)	<0.001	2.15 (1.52– 3.04)	<0.001

Abbreviations: HR, hazard ratio; CI, confidence interval; ref, reference; SMV/PV, superior mesenteric vein/portal vein